Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Doubled-Blind, Placebo-Controlled Trial to Evaluate Safety, Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Next Previous
Search
Trial Profile

A Phase 2a Randomized, Doubled-Blind, Placebo-Controlled Trial to Evaluate Safety, Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegtarazimod (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors ReAlta Life Sciences

    • Most Recent Events

    • 13 Nov 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
    • 13 Nov 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
    • 21 Feb 2024 According to a ReAlta Life Sciences media release, company announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) in hospitalized patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top